Organic Active Ingredients TRIZ Cases

Indazole benzimidazole derivative binds FLT3 ATP pocket to resolve selectivity and activity trade-offs for leukemia treatment.

Formula I macrocycles inhibit ALK, ROS1, and EGFR kinases to resolve limited therapeutic options for kinase-mediated diseases.

Combines berberine with omega-3 fatty acids to create a pharmaceutical composition for treating inflammatory bowel disease.

Ester prodrugs of bicyclohexane dicarboxylic acid derivatives enhance membrane permeability and in vivo exposure.

Bifunctional PROTAC compounds recruit E3 ligases to tag the estrogen receptor for proteasomal breakdown, eliminating partial agonist effects.

RICE01 selectively inhibits phosphodiesterase 4D to promote remyelination and prevent cognitive decline in neurodegenerative disorders.

A microbubble complex delivers sonosensitizers and chemotherapeutic agents to tumor sites via ultrasound activation.

Lipophilic nucleoside phosphoramidates bypass initial phosphorylation to increase intracellular active monophosphate concentrations.

Segmenting the liposome into a stable nuclear core and affinity-enhanced shell resolves delivery efficiency versus structural stability contradictions.

Filamin A binding compounds stabilize mu opioid receptor Gi/o coupling to prevent inflammatory responses and analgesic tolerance.

HIF prolyl hydroxylase inhibitors replace recombinant therapy by stimulating endogenous erythropoietin production, reducing treatment complexity and risks.

Enzymatic transglutamination achieves homogeneous antibody drug conjugates without altering native glycosylation patterns.

Sotorasib Form A resolves the contradiction between storage reliability and dissolution rates by optimizing crystal phase transitions.

Dual-domain EF-hand polypeptides chelate intracellular calcium, resolving specificity issues in optogenetic and pharmacological approaches.

A cross-linked hyaluronic acid polymer uses a tetrazine linker to join chains via unsaturated moieties.

Peptide drug conjugates hydrolyze to sequester cytotoxic metabolites, resolving the trade-off between systemic toxicity and tumor targeting specificity.

Solubilized estradiol in medium chain oil soft gel capsules reduces vaginal discharge and irritation while maintaining therapeutic efficacy.

A sublingual pharmaceutical composition delivers eliglustat through the mucosal membrane to increase bioavailability.

Formula I macrocycles lower toxicity while clearing viral RNA to treat chronic hepatitis C infections.

Linked antisense oligonucleotide compound targets exon 51 sequences to enhance skipping efficiency.

Composite ethyl cellulose and pore-forming agent coatings eliminate lag phase in metoprolol sustained-release pellets.

Combining sGC stimulators with activators restores cGMP production in oxidized enzyme states, reducing side effects from high-dose monotherapy.

Benzothiazole derivatives bind keratin to retain active agents, resolving inefficient delivery and retention in conventional methods.

Converting crystalline cabazitaxel into an amorphous state through solvent evaporation to enhance bioavailability and stability.

Local lithium application resolves the contradiction between effective anti-inflammatory action and hepatic or renal impairment risks.

Azelaic acid binds the Olfr544 GPCR to activate cAMP-PKA-HSL signaling, reducing lipid accumulation without severe side effects.

Formula A benzoxazolinone compounds selectively inhibit Nav1.7 channels to treat chronic pain without affecting Nav1.5 channels.

Replacing gadolinium with manganese bisphosphonate complexes eliminates nephrogenic systemic fibrosis risks while maintaining high MRI signal enhancement.

Replacing aluminum adjuvants with calcium phytate microparticles strengthens antigen binding and reduces side effects while maintaining immune response.

Moisture-barrier packaging isolates pemafibrate from humidity, preventing cellulose interactions that increase decomposition products.

Mutated AAV-8 capsids enhance transduction efficiency to deliver pre-miR-101, silencing EzH2 expression and reducing tumor metastasis without systemic toxicity.

Segmented pyrazolo-pyrimidine derivatives target altered SYK activity to treat non-Hodgkin's lymphomas and immune disorders.

A therapeutic agent for amyotrophic lateral sclerosis utilizes motor neurons derived from patient-specific induced pluripotent stem cells to identify effective compounds.

Novel autotaxin inhibitors block lysophosphatidylcholine hydrolysis, addressing inadequate therapies for fibrotic diseases.

NSI-189 benzylpiperazine aminopyridine agent treats depression by targeting patients with impaired learning and memory or specific EEG patterns.

An inhaled flecainide composition achieves rapid cardioversion while minimizing adverse cardiac events associated with high-dose systemic administration.

Compounds targeting phosphorylated vimentin disrupt intermediate filament organization to induce mitotic catastrophe in mesenchymally-transformed cancer cells.

Extruded cholestyramine pellets with non-aqueous coatings deliver drugs to the colon, reducing gastrointestinal side effects.

Segmenting treatment into multiple agents prevents drug resistance while maintaining protocol simplicity through universal multi-target inhibition.

Pharmaceutical composition combines noble gas isotopes with respiratory stimulants to inhibit proprotein convertases.

Administering fucosylated oligosaccharides reduces upper respiratory tract infection incidence and severity in high-risk infants born to non-secretor mothers.

Glial activating compounds induce brain-derived neurotrophic factor release to restrain TLR4 signaling and prevent necrotizing enterocolitis.

Compounds targeting TRADD block apoptosis without triggering necroptosis while activating autophagy to clear misfolded proteins.

A method assesses albumin-based paclitaxel pharmaceutical compositions by measuring specific physicochemical characteristics.

UBE2T epitope peptides overcome immune self-recognition to induce specific cytotoxic T lymphocyte responses against tumors.

Lyophilized cyclosporine A liposomes resolve low solubility and systemic toxicity through disaccharide stabilization.